한국인 치과의사의 비스포스포네이트 관련 악골괴사에 대한 인식 연구 : 예비보고

AWARENESS OF KOREAN DENTISTS ON BISPHOSPHONATE RELATED OSTEONECROSIS OF THE JAWS : PRELIMINARY REPORT

  • 박용덕 (경희대학교 치의학전문대학원 예방사회치과학교실) ;
  • 김영란 (경희대학교 치의학전문대학원 구강악안면외과학교실) ;
  • 김덕윤 (경희대학교 치의학전문대학원 핵의학과) ;
  • 정윤석 (아주대학교 의과대학 내분비대사내과) ;
  • 이정근 (아주대학교 의과대학 치과 구강악안면외과) ;
  • 김여갑 (경희대학교 치의학전문대학원 구강악안면외과학교실) ;
  • 권용대 (경희대학교 치의학전문대학원 구강악안면외과학교실)
  • Park, Yong-Duck (Department of Preventive and Public Health Dentistry, School of Medicine, Kyung Hee University) ;
  • Kim, Young-Ran (Department of Oral & Maxillofacial Surgery, School of Dentistry, School of Medicine, Kyung Hee University) ;
  • Kim, Deog-Yoon (Department of Nuclear Medicine, School of Medicine, Kyung Hee University) ;
  • Chung, Yoon-Sok (Department of Endocrinology, Ajuo University School of Medicine) ;
  • Lee, Jeung-Keun (Department of Dentistry, Ajuo University School of Medicine) ;
  • Kim, Yeo-Gab (Department of Oral & Maxillofacial Surgery, School of Dentistry, School of Medicine, Kyung Hee University) ;
  • Kwon, Yong-Dae (Department of Oral & Maxillofacial Surgery, School of Dentistry, School of Medicine, Kyung Hee University)
  • 발행 : 2009.06.30

초록

Recently, an increasing number of bisphosphonate related osteonecrosis of the jaw(BRONJ) is being reported. A guideline has been already established in the US, but it does not seem to be fully recognized by clinicians in Korea. Therefore, a survey study was done to inform and have clinicians realize the seriousness of BRONJ. 1,341 practitioners were randomly selected out of 13,405 practitioners(by Feb of 2008, KDA) in Korea. A questionnaire was given to them between May to July in 2008. Questions were designed to investigate each respondent's experience term years in the clinic, occupation, speciality, awareness on risk of bisphosphonate, experience on treating osteonecrosis patients, awareness about the guideline on BRONJ suggested by AAOMS and whether if they ask about bisphosphonate medication history to patients before invasive treatment. 45.1% of the clinicians have reported on experiencing delayed healing on bone exposed site after extraction both in the maxilla and the mandible. However, clinicians have asked the patients whether if they are on bisphosphonate or not in only 15.1% of these cases. 56.5% of the clinicians simply knew about BRONJ but only 28.9% of the clinicians were aware that bisphosphonate can cause osteonecrosis after invasive dental treatment. Only 19.3% knew about the contents of guideline on BRONJ and 57.2% were aware of the seriousness of BRONJ. Clinicians with shorter clinical experience term were more aware of BRONJ and the guideline on BRONJ than the experienced clinicians. But awareness of the possibility of BRONJ after invasive dental treatment were about the same regardless of their clinical experience. The results show that Korean clinicians need to be more aware about BRONJ. Data on BRONJ cases in Korea should be collected and provided with additional education to let Korean clinicians know and be more aware about BRONJ.

키워드

참고문헌

  1. http://www.nso.go.kr/
  2. 국민건강보험공단 2007통계연보, 대한민국, 2008
  3. Bize R, Lamy O, Peytremann-Bridevaux I. Osteoporotic fracture in menopausal women: alendronate reduces the risk. Rev MedSuisse. 2008 Dec 10;4:2703
  4. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) inducedavascular necrosis of the jaw : a growing epidemic. J OralMaxillofac Surg 2003;61:1115-7 https://doi.org/10.1016/S0278-2391(03)00720-1
  5. Dimitrakopoulos I. Magopoulos C, Karakasis D. Bisphos-phonateinducedavascular osteonecrosis of the jaws: a clinical report of 11cases. Int J Oral Maxillofac Surg 2006;35:588-93 https://doi.org/10.1016/j.ijom.2006.02.022
  6. Ruggiero SL. Mehrotra B. Rosenberg TJ. Osteonecrosis of thejaws associated with the use of bisphosphonates : a review of 63cases. J Oral Maxillofac Surg 2004;62:527-34 https://doi.org/10.1016/j.joms.2004.02.004
  7. Bagan JV, Murillo J, Jimenez Y. Avascular jaw osteonecrosis inassociation with cancer chemotherapy : series of 10 cases. J OralPathol Med 2005;34:120-3 https://doi.org/10.1111/j.1600-0714.2004.00269.x
  8. American Association of Oral & Maxillofacial Surgeons. 2006 position paper on Bisphosphonate-related osteonecrosis of the jaw. Available at http://www.aamos.org/2006
  9. Kwon YD, Yoon BW, Walter C. Bisphosphonate, is it an emergingrisk factor in oral surgery? J Korean Assoc Maxillofac PlastReconstr Surg 2007;29:456-62
  10. Haderslev KV, Tjellesen L, Sorensen HA et al. Alendronate increaseslumbar spine bone mineral density in patients withCrohn's disease. Gastroenterology 2000;119:639-46 https://doi.org/10.1053/gast.2000.16518
  11. National Osteoporosis Foundation. American's Bone Health. Available at http://nof.org/advocacy/prevalence/index.htm
  12. Grotz KA. Zahnarztliche Betreuung von Patienten mit tumortherapeutischerKopf-Hals-Bestrahlung (Stellungnahme der DGZMKund DEGRO). Dtsch Zahnrztl Z. 2002;57:509
  13. Hansen T, Kunkel M, Weber A, James Kirkpatrick C.Osteonecrosis of the jaws in patients treated with bisphosphonates-histomorphologic analysis in comparison with infected osteoradionecrosis.J Oral Pathol Med 2006;35:155-60 https://doi.org/10.1111/j.1600-0714.2006.00391.x
  14. Altundag K, Bulut N, Tezcan E, Ozen M, Purnak T. Tooth extraction: Is it inciting event or sequela of osteonecrosis of the jaws associated with intravenous bisphosphonates? J OralMaxillofac Surg 2007;65:154 https://doi.org/10.1016/j.joms.2006.07.015
  15. Groetz KA, Al-Nawas B. Persisting alveolar sockets-a radiologic symptom of BP-ONJ. J Oral Maxillofac Surg 2006;64:1571-2 https://doi.org/10.1016/j.joms.2006.05.041
  16. Schilling J. Management of bisphosphonate-induced osteonecrosis of the jaw. Northwest Dent. 2008;87:34-5,37-8, 40
  17. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JAet al. Once-yearly zoledronic acid for treatment of postmenopausalosteoporosis. N Eng1 J Med 2007;356:1809-22 https://doi.org/10.1056/NEJMoa067312
  18. Walter C, Grotz KA, Kunkel M, Al-Nawas B. Prevalence of bisphosphonateassociated osteonecrosis of the jaw within the fieldof osteonecrosis. Support Care Cancer 2007;15:197-202 https://doi.org/10.1007/s00520-006-0120-z